Navigation Links
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis

ere adjudicated by a blinded, independent central adjudication committee. The study was not powered to show a dose response with PRT054021 or efficacy of PRT054021 versus enoxaparin.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an anticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a twenty hour pharmacodynamic half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function. PRT054021 is expected to enter Phase III clinical development in the first half of 2008.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascular disease. Portola is currently developing two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and stroke. Portola's second compound, PRT060128, is an o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:3/26/2015)... -- Desert Valley Medical Center, named a Top 100 Hospitals® ... first U.S. hospital to deploy the wireless Leaf Patient ... prevent hospital acquired pressure ulcers. Desert Valley, ... a community hospital serving some higher risk populations, including ... in the hospital,s emergency department enables the clinical staff ...
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
Breaking Medicine Technology:Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2Finesse Solutions annonce l'événement Cellworld 2015 2
... 2012  Delcath Systems, Inc. (NASDAQ: DCTH ) today ... of credit revolver with Silicon Valley Bank ("SVB"), a leading ... facility is available for general corporate purposes supporting the overall ... on the transaction, Eamonn P. Hobbs, President & CEO of ...
...  Trovagene, Inc. (Pink Sheets:  TROV.PK), a developer of ... McCormick as head of commercial operations, effective April ... and diagnostic sales, marketing and operational experience. Most ... operations at bioTheranostics, Inc.  McCormick served as a ...
Cached Medicine Technology:Delcath Systems, Inc. Secures $20 Million Credit Facility 2Delcath Systems, Inc. Secures $20 Million Credit Facility 3Delcath Systems, Inc. Secures $20 Million Credit Facility 4Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations 2Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations 3
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), ... of medical cannabis as a treatment for patients ... clinics dedicated to providing access to safe medical ... patients searching for medical marijuana treatment in legal ... sub domain for Canada. , With the ...
(Date:3/27/2015)... The Florida Center for Brain Tumor ... (ABC2), awarded $350,000 to support brain cancer research at ... Research Institute and H. Lee Moffitt Cancer Center and ... clear development path and potential to provide meaningful improvements ... , The awards fund research in areas on ...
(Date:3/26/2015)... Let’s not lose focus of why ... today’s traffic magnets. Three out of 4 consumers choose ... produce department, according to a Packaged Facts survey. Produce ... looking to add more fruits and vegetables to their ... is April 2. As featured in the Chase’s Calendar ...
(Date:3/26/2015)... The American College of Traditional Chinese Medicine announces several ... DAOM Program as well as Marketing Basics for Healers & ... by Dr. Carla Wilson, who will give an overview of ... prepare for the spring quarter. The webinar will be from ... and April 3. Attendees can log in from work or ...
(Date:3/26/2015)... Building off their success and ... the Cardiometabolic Risk Summit and ... are proud to announce a pioneering professional ... interdisciplinary program , which ultimately grants a Certified ... physicians, nurse practitioners, physician assistants, registered dietitians, and ...
Breaking Medicine News(10 mins):Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3Health News:ACTCM Announces Upcoming Webinars 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
... older women - those 80 or older - have the greatest ... today. ,Worryingly, the research also found that 56 per ... cancer risk. ,The strongest risk factor for breast cancer ... her risk. About one in 70 women will develop breast cancer ...
... risk of cancer; a Danish study conducted amongst 28,000 ... ,Danish medical records were analyzed to monitor ... among the utility workers for 23years. This was done ... and its effects. ,The researchers did not ...
... definite link between pregnancy, migraine and stroke, US researchers ... one. ,In fact, Cheryl Bushnell, assistant professor ... Disease in Durham, explained that pregnant women who suffered ... than pregnant women who did not suffer migraine. ...
... talked about testosterone cream for enhancing sexual desire in female ... conducted by Mayo clinic has shown. ... As an extension to a previous study which pointed a ... with sufficient estrogen levels, this new study was conducted on ...
... one out of depression. But its potential to drive ... ,Now the U.S. Food and Drug Administration (FDA) ... the existing black box warning on their products' labeling ... and behavior, in young adults ages 18 to 24 ...
Cached Medicine News:Health News:Sleep Deprivation can Affect Competent Decision-making 2Health News:Women Unaware of When Breast Cancer Risk is Greatest 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: